Back

Insilico’s rentosertib enters Phase III after 98.4 mL lung-function gain

Verifying
  • Insilico Medicine began Phase III testing of rentosertib for IPF on July 7, 2026.
  • 98.4 mL was the mean 12-week FVC increase at the 60 mg dose.
  • 47 Chinese centers enrolled approximately 320 patients in the Phase III trial.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.
Insilico’s rentosertib enters Phase III after 98.4 mL lung-function gain - CoinPost Terminal